{"id":6368,"date":"2014-04-08T21:28:30","date_gmt":"2014-04-08T13:28:30","guid":{"rendered":"https:\/\/canadianinquirer.net\/v1\/?p=6368"},"modified":"2014-04-08T21:28:30","modified_gmt":"2014-04-08T13:28:30","slug":"japan-pharmaceutical-company-takeda-penalized-over-diabetes-drug-plans-to-challenge-verdict","status":"publish","type":"post","link":"https:\/\/canadianinquirer.net\/v1\/2014\/04\/08\/japan-pharmaceutical-company-takeda-penalized-over-diabetes-drug-plans-to-challenge-verdict\/","title":{"rendered":"Japan pharmaceutical company Takeda penalized over diabetes drug, plans to challenge verdict"},"content":{"rendered":"<p><span class=\"Apple-style-span\" style=\"color: #000000; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: #ffffff; font-size: medium;\"><span class=\"ArticleTitle\"><a href=\"https:\/\/canadianinquirer.net\/v1\/wp-content\/uploads\/2014\/03\/shutterstock_121636234.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-3765\" alt=\"shutterstock_121636234\" src=\"https:\/\/canadianinquirer.net\/v1\/wp-content\/uploads\/2014\/03\/shutterstock_121636234.jpg\" width=\"500\" height=\"335\" srcset=\"https:\/\/canadianinquirer.net\/v1\/wp-content\/uploads\/2014\/03\/shutterstock_121636234.jpg 500w, https:\/\/canadianinquirer.net\/v1\/wp-content\/uploads\/2014\/03\/shutterstock_121636234-300x201.jpg 300w\" sizes=\"auto, (max-width: 500px) 100vw, 500px\" \/><\/a><\/span><span class=\"Date\"><br \/>\n<\/span><\/span><\/p>\n<hr align=\"left\" width=\"90%\" \/>\n<p>TOKYO &#8211; A U.S. jury ordered Takeda Pharmaceuticals to pay $6 billion in punitive damages over a diabetes drug, but Japan&#8217;s biggest drug-maker is challenging the move.<\/p>\n<p>The District Court, Western District Louisiana, on Tuesday also ordered a $3 billion penalty for co-defendant Eli Lilly, as well as $1.5 million in compensatory damages.<\/p>\n<p>The legal fight was over Actos, a drug used to treat diabetes, as causing a patient&#8217;s bladder cancer.<\/p>\n<p>Takeda Senior Vice-President Kenneth Greisman said in a statement that Takeda disagrees with the verdict and plans post-trial motions and an appeal.<\/p>\n<p>He said he empathized with the plaintiff but the drug did not cause his cancer.<\/p>\n<p>The drug comes with warnings about serious side effects, including liver problems, broken bones and higher risk of bladder cancer.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>TOKYO &#8211; A U.S. jury ordered Takeda Pharmaceuticals to pay $6 billion in punitive damages over a diabetes drug, but &hellip;<\/p>\n","protected":false},"author":44,"featured_media":3765,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[19],"tags":[561,1890,380,1891,667,1892,1889],"class_list":["post-6368","post","type-post","status-publish","format-standard","has-post-thumbnail","category-business","tag-as","tag-diabetes","tag-drug","tag-eli","tag-japan","tag-lilly","tag-takeda","mauthors-the-associated-press"],"_links":{"self":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts\/6368","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/users\/44"}],"replies":[{"embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/comments?post=6368"}],"version-history":[{"count":0,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts\/6368\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/media\/3765"}],"wp:attachment":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/media?parent=6368"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/categories?post=6368"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/tags?post=6368"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}